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ABBREVIATIONS 
 
1. CKD  – chronic kidney disease 
2. FGF 23  – fibroblast growth factor 
3. GFR – glomerular filteration rate 
4. GN  – glomerulonephritis 
5. ANCA  – anti neutrophil cytoplasmic antibody 
6. COL4A5  – gene encoding alpha 5 chain of type V basement 
  membrane collagen 
7. FSGS  – focal segmental glomerulosclerosis 
8. MHC  – major histocompatibility complex 
9. TGF-β  – transforming growth factor β 
10. CTGF  –  connective tissue growth factor 
11. ECM  – extra cellular matrix 
12. PDGF  –  platelet derived growth factor 
13. CSGF  – colony stimulating growth factor 
14. NADP+  – nicotinamide adenine dinucleotide phosphate 
15. EMT  – epithelial mesenchymal transition 
16. CD  – cluster of differentiation 
17. CCR5  – chemokine receptor 5 
18. CxCR3  –  chemokine receptor 
19. EGF  – epidermal growth factor 
20. ET-1  –  endothelin 1 
21. HIF  –  hypoxia inducible factor 
22. MCP 1  – monocyte chemoattractant protein 1 
23. RANTES  – regulated on activation normal T cell expressed and  
  secreted 
24. MDRD  – modification of diet in renal disease 
25. CKD EPI  – chronic kidney disease epidemiology collaboration 
26. KL  – klotho 
27. PTH  – parathyroid hormone 
28. NaPi–2a  – sodium phosphate co transporter 
29. TRPV 5 –  transient receptor potential vanilloid channel 
30. ROMK  –  renal outer medullarypotassium 
31. ADAM  –  A disintegrin and metalloproteinase 
32. RAA –  renin angiotensin aldosterone system 
33. IL  –  interleukin 
34. Smad II  –  small worm phenotype and mothers against  
  decapentaplegic 
35. Pit 1 and Pit 2 –  type III sodium dependent phosphate transporters 
36. FGFR 1  – fibroblast growth factor receptor 
37. GALNT 3  – polypeptide N – acetyl galactosaminyltransferase 3 
38. HS – heparansulphate 
39. BaF3  – murine interleukin 3 dependent pro B cell line 
40. MAPK  – mitogen activated protein kinase 
41. HEK 293  –  human embryonic kidney cells 
42. ESRD  – end stage renal disease 
43. TNAP  –  tissue non-specific alkaline phosphatase 
44. FEP  – fractional excretion of phosphate 
45. ERK  – extracellular signal regulated kinase 
46. NF-κ  – nuclear factor kappa 
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INTRODUCTION 
 
Chronic kidney disease is an emerging public health problem with global 
prevalence between 11 to 13%. There is a paucity of sensitive biomarkers to 
diagnose early CKD and there are few specific and effective approaches to retard 
CKD progression and prevention of extra-renal complications. 
 
Pathological variations of Klotho / FGF 23 in chronic kidney disease are 
implicated as clinical biomarkers and may bring forth novel therapeutic strategies 
to reduce the cardiovascular risk and slow down the progression of damage to 
kidney. Chronic kidney disease – mineral and bone disorder causes abnormalities 
in bone and mineral metabolism or extra skeletal calcification(1). The FGF 23 / 
Klotho endocrine axis plays a vital role in mineral metabolism. Serum FGF 23 
level increases early in chronic kidney disease before the increase of serum 
phosphate or parathyroid hormone. In CKD early onset of Klotho deficiency 
contributes to renal FGF 23 resistance and a maladaptive increase in circulating 
FGF 23. FGF 23 is an early marker of renal injury, increased levels of which 
predicts adverse clinical outcomes in particular cardiovascular disease. α Klotho 
functions as an obligatory co-receptor for FGF 23 along with FGF receptor to 
transduce FGF 23 signaling to regulate calcium and phosphate metabolism as a 
calico-phosphotrophic hormone. 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
 
CKD definition 
 “CKD is defined as abnormalities of kidney structure or function, present 
for more than 3 months, with implications for health”(2). 
 
Criteria for CKD (either of the following present for more than 3 months) 
 
Markers of kidney damage 
 Albuminuria 
 Urine sediment abnormalities 
 Electrolyte and other abnormalities due to tubular pathology 
 Abnormalities detected by histology 
 Structural abnormalities identified by imaging 
 History of transplantation of kidney 
 
Decreased GFR 
 GFR < 60 mL/min/1.73m2 (GFR categories G3a-G5)(3). 
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Classification of CKD based on presence or absence of systemic disease and 
location within the kidney of pathologic anatomic findings 
Systemic diseases affecting the kidney Primary kidney disease 
Glomerular 
diseases 
Diabetes, systemic 
autoimmune disease, 
systemic infections, drugs, 
neoplasia (including 
amyloidosis) 
Diffuse, focal or crescentic 
proliferative GN; focal and 
segmental glomerulosclerosis, 
membranous nephropathy, 
minimal change disease 
 
Tubulointerstitial 
diseases 
Systemic infections, 
autoimmune, sarcoidosis, 
drugs, urate, 
environmental toxins 
Urinary tract infections, stones, 
obstruction 
Vascular diseases 
Atherosclerosis, 
hypertension, ischemia, 
systemic vasculitis, 
thrombotic 
microangiopathy, systemic 
sclerosis 
ANCA-associated renal limited 
vasculitis, fibromuscular 
dysplasia 
Cystic and 
congenital 
diseases 
Polycystic kidney disease, 
Alport syndrome, Fabry 
disease 
Renal dysplasia, 
medullarycystic 
disease,podocytopathies 
 
GFR categories in CKD 
GFR Category GFR (mL/min/1.73m2) Terms 
G1 >90 Normal or high 
G2 60–89 Mildly decreased 
G3a 45–59 Mildly to moderately decreased 
G3b 30–44 Moderately to severely decreased 
G4 15–29 Severely decreased 
G5 < 15 Kidney failure 
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Pathophysiology of kidney disease 
 The pathophysiology of CKD is discussed along with renal anatomical and 
physiological characteristics, in addition to the mechanisms of renal tissue injury 
and repair. 
 
1. The rate of renal blood flow is roughly about 400mL/100g of tissue per 
minute, which is much beyond that observed in other well perfused organs 
such as heart, liver and brain. Consequently, renal tissue is exposed to a 
significant quantity of potentially noxious circulating agents or 
substances(4). 
 
2. Glomerular filtration depends on high intra and trans glomerular pressure 
(even in stable physiologic conditions), making the glomerular capillaries 
more prone to hemodynamic injury, contrary to other capillary beds. 
Glomerular hypertension and hyperfiltration are the main reasons for 
chronic renal disease progression. 
 
3. Glomerular filtration membrane has negatively charged molecules at the 
surface, which acts as a barrier to anionic molecules. When this 
electrostatic barrier is damaged as a consequence of glomerular injury, 
plasma proteins will enter the filtrate. 
 
4. The sequential arrangement of nephrons microvasculature (glomerular 
convolute and the network of peritubular capillaries) and the subsequent 
position of tubule in regard to glomeruli not only sustain the glomerulo-
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tubular balance but also promote the spread of glomerular injury to the 
tubulointerstitial compartment, exposing tubular epithelium to abnormal 
ultra-filtrate. The peritubular vasculature underlies glomerular circulation, 
and glomerular inflammatory mediators following injury may overflow 
into the peritubular circulation contributing to the subsequent interstitial 
inflammatory reaction in glomerular disease. 
 
Any reduction in pre-glomerular or glomerular perfusion leads to reduction 
in peritubular blood flow which, depending on the extent of hypoxia, 
evokes tubulointerstitial injury and tissue remodeling. 
 
5. The glomerulus should be viewed as a functional unit with each of its 
constituents (endothelial, mesangial, visceral and parietal epithelial cells – 
podocytes and extracellular matrix) performing an integral part of normal 
function. Damaging one will affect the other through various mechanisms, 
direct cell – cell interaction(e.g., gap junctions), soluble mediators such as 
chemokines, cytokines, growth factors and changes in matrix composition 
and basement membrane(4). 
 
Major causes of renal injury are 
1. Immunologic reactions (initiated by immune cells or immune complexes) 
2. Tissue hypoxia and ischemia 
3. Exogenous agents like drugs 
4. Endogenous substances like glucose or para-proteins and others 
5. Genetic defects 
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 Regardless of the cause, glomerulosclerosis and tubulointerstitial fibrosis 
are main features of CKD. 
 
 The pathophysiology of CKD involves specific consideration to 
mechanisms of glomerular, tubular and vascular injury. 
 
MECHANISMS OF GLOMERULAR IMPAIRMENT 
Hereditary defects 
 It contributes to minor proportion of CKD. Classical example is Alport 
syndrome, which involves mutation in the COL4A5 gene that encodes the α5 
chain of type4 collagen. As a consequence, glomerular basement membrane is 
irregular with longitudinal layering, splitting or thickening and the patient 
develops progressive glomerulosclerosis and renal failure. Other causes include 
thin membrane syndrome, nail–patella syndrome, partial lipodystrophy and 
familial lecithin–cholesterol acyl transferase deficiency. 
 
Acquired glomerular disease 
  It is triggered by immune mediated injury, and metabolic and mechanical 
stress. From the pathologic point of view, it can be broadly divided into three 
groups 
1. Non-proliferative 
2. Proliferative 
3. Heterogeneous 
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1. Non-proliferative (without cell proliferation) glomerular disease without 
glomerular inflammation and without deposition of immunoglobulin[minimal 
change disease, idiopathic focal, and segmental glomerulosclerosis (FSGS) or 
with deposition of immunoglobulin, but without glomerular inflammation, 
most likely because of subepithelial localization of immunoglobulin e.g., 
membranous nephropathy] 
 
2. Proliferative glomerular disease with deposition of immunoglobulins leading 
to increased cellularity e.g., lupus nephritis, IgA nephropathy, anti –glomerular 
basement membrane, post infectious GN), or with severe glomerular injury 
and inflammation, but without deposition of immunoglobulin (e.g., pauci-
immune glomerulonephritis) 
 
3. Heterogenous group of glomerular diseases in systemic diseases like diabetes, 
amyloidosis and paraproteinemia. 
 
 Tissue injury after immune complex deposition is mediated through 
complement activation resulting in the formation of C5-9 membrane attack 
complex which appears to be the major effector of glomerular injury through 
release of chemo tactic C5a and C3a. C5-9-activated cells release chemokines and 
oxidant proteases, and upregulate adhesion molecules. 
 
T- cells also mediate golomerular injury by the production of nephritogenic 
antibodies, especially in pauci-immune GN. They interact through their surface 
receptor /CD3 complex with antigens presented in the clefts of MHC molecules of 
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endothelial, mesangial and epithelial glomerular cells. Once activated T-cells 
release cytokines and other inflammatory mediators it causes cytotoxicity and 
fibrogenesis. 
 
TGF-β and connective tissue growth factor (CTGF) are important in 
glomerular fibrogenesis as they stimulate production of extracellular matrix 
(ECM) a key event in the progression of kidney disease, inhibiting tissue 
proteases. 
 
 Glomerular inflammation can either completely recover or resolve with a 
variable degree of fibrosis. The resolution process requires  
- Cessation of further antibody production and immune complex formation 
- Degradation and removal of deposited and circulating immune complexes. 
- Cessation of recruitment and clearing, of inflammatory cells 
- Dispersing of inflammatory mediators 
- Normalization of endothelial adhesiveness, permeability and vascular tone 
- Clearance of proliferating residual glomerular cells 
 
NON-IMMUNOLOGIC GLOMERULAR INJURY 
 Hemodynamic, metabolic and toxic injuries can induce glomerular 
impairment alone or in combination with immunological processes. 
 
SYSTEMIC HYPERTENSION 
 The kidney is normally protected from systemic hypertension by 
autoregulation, which can be overwhelmed by high blood pressure, systemic 
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hypertension translated directly to glomerular filtration barrier causing glomerular 
injury. Chronic hypertension will lead to arteriolar vasoconstriction and sclerosis 
with consequent secondary sclerosis and glomerular and tubulointerstitial atrophy. 
Different growth factors like angiotensin II, EGF, PDGF, CSGF, TGF –β 
CYTOKINE, activation of stretch activated ion channels and early response 
genes, are involved in coupling high blood pressure to myo-intimal proliferation 
and vessel wall sclerosis. 
 
GLOMERULAR HYPERTENSION 
 It is normally an adaptive response mechanism in remaining nephrons to 
increased workload resulting from loss of nephrons, whatever may be the cause. 
This sustained intraglomerular hypertension increases the mesangial matrix 
production and leads to glomerulosclerosis by ECM accumulation. 
 
Metabolic injury: 
 Three mechanisms have been postulated to explain the effect of 
hyperglycemia in tissue damage. 
 
1) Advanced glycated end products: 
 Glucotoxicity leads to the formation of advanced glycation end products by 
non enzymatic glycosylation of intracellular proteins where glucose & other 
glycating compounds attach to amino group and other molecule such as nucleic 
acid without the aid of enzyme, producing reversible early glycated end products 
(Schiff’s base) and later, irreversible (Amadori products). 
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 These products are slowly converted into advanced glycated end products. 
 
 It accumulates in tissue (arterial wall and glomerular basement membrane) 
by cross linking with the collagen causing atherosclerosis and glomerular 
dysfunction. 
 
 It alters the signal transduction by altering the level of cytokines, hormones 
and free radicals to contribute the renal and micro vascular complications. 
 
2) Protein kinase C pathway: 
 Hyperglycemia activates protein kinase c by de novo formation of diacyl 
glycerol and oxidative stress, leading to secretion of vasodilatory prostanoids, 
TGF-β1 which contributes to glomerular hyper filtration and mesangial cell 
expansion. 
 
3) Polyol pathway: 
 When intracellular glucose concentration is raised, glucose metabolism 
takes place via sorbitol pathway by the enzyme aldose reductase. It is present in 
mesangial cells, distal tubular cell, and glomerular epithelial cell of normal 
kidney. It generates sorbitol in response to high salinity in medullary interstitium. 
 Sorbitol causes 
-defect in inositol signaling. 
-depletion of myo inositol. 
-decreased Na+K+ ATPase activity. 
-decreased intracellular NADPH leading on to oxidative injury. 
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MECHANISM OF TUBULOINTERSTITIAL IMPAIRMENT 
The impairment of the tubulointerstitium (tubulointerstitial fibrosis and 
tubular atrophy) is, as important as glomerulosclerosis as tubules and interstitium 
constitute more than 90% of kidney volume. 
 
Tubulointerstitial fibrosis has the following characteristic features: 
- inflammatory cell infiltrate which results from both activation of resident 
inflammatory cells and recruitment of circulating inflammatory cells. 
- an increase in interstitial fibroblasts due to increased proliferation and 
decreased apoptosis of resident interstitial cells 
- the appearance of myo fibroblasts expressing the cytoskeletal protein α-
smooth muscle actin, which arise by differentiation of resident interstitial 
fibroblasts and infiltrating cells and via trans-differentiation. 
- accumulation of extracellular matrix (ECM) as the net result of increased 
synthesis of ECM components and decreased ECM degradation mostly by 
specific metalloproteinase that are under the control of specific inhibitors. 
- tubular atrophy as a consequence of apoptosis and epithelial-mesenchymal 
trans-differentiation (EMT) and rarefaction of peritubular capillaries. 
 
 The development of fibrosis is associated with an increase in the 
expression of proinflammatory, vasoconstrictive and profibrotic factors(5). 
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Renal fibrogenesis: 
 The initial insult leads to inflammatory response with the release of 
inflammatory mediators, an increase in local vascular permeability, activation of 
endothelial cells, extravasation of leukocytes along the endothelium, subsequent 
secretion of various mediators by leukocytes and tubulointerstitial cells and 
activation of pro-fibrotic cells. A vicious cycle of cell stress is initiated generating 
pro-fibrotic and pro-inflammatory mediators, leukocyte infiltration and fibrosis. 
 
Induction and development of the inflammatory response 
 Leukocytes infiltrate into interstitium following gradients of 
chemoattractants and chemokines. The factors involved in the formation of 
tubulointerstitial inflammatory infiltrates are proteinuria, immune deposits, 
chemokines, cytokines, calcium, phosphate, metabolic acidosis, uric acid, lipids, 
hypoxia and reactive oxygen species. 
 
 Inflammatory cells are composed of monocytes / macrophages and 
lymphocytes, particularly T lymphocytes (CD4 – positive T cells and CD3 T cells 
carrying chemokine receptors CCR5 and CxCR3). 
 
 The pro-fibrotic factors involved in renal fibrogenesis are angiotensin II, 
TGF-β1, CTGF, PDGF, FGF2, EGF, ET-1, tryptase mast cell. TGF-β is the key 
cytokine in renal fibrogenesis. 
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Epithelial–mesenchymal transition: 
 Phenotypic conversion of epithelial cells into mesenchymal cells is known 
as the epithelial–mesenchymal transition. Evidence is based upon the utilization 
of mesenchymal marker proteins such as vimentin or S100A4, the human 
analogue of fibroblast specific protein – 1. It is also shown that hypoxia-inducible 
factor-1 (HIF-1) is the master regulator of the adaptive response controlling the 
expression of many genes and also stimulates EMT, which explains why hypoxia 
results in fibrosis and progressive renal failure. Prolonged exposure to hypoxia 
leads to mitochondrial injury and apoptosis consistent with the loss of tubular 
cells. Changes in HIF expression correlate with the extent of tubulointerstitial 
injury(5). 
 
Proteinuria and tubulointerstitial damage 
 Proteinuria can damage tubulointerstitium through multiple pathways 
including direct tubular toxicity, changes in tubular epithelial metabolism, 
induced cytokine and chemokine synthesis and increased expression of adhesion 
molecules (Abbate). Excess protein reabsorption in proximal tubule may exceed 
lysosomal processing capacity leading to lysosomal rupture and direct tubular 
toxicity. The mechanisms include generation of chemotactic factor for 
macrophages, secretion of chemokines such as monocyte chemoattractant  
protein -1 and RANTES, and expression of fractalkine (a chemokine promoting 
mononuclear cell adhesion). Proteinuria also induces the secretion of TGF-β as 
well as that of  intercellular adhesion molecule -1 and vascular adhesion  
molecule -1(6). 
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MEASUREMENT OF GFR: 
 National kidney foundation recommends that glomerular filtration rate 
estimation is necessary for diagnosis, screening, classification and monitoring of 
chronic kidney disease. Without GFR measurements, CKD may remain silent and 
the patient will land up in end stage renal disease.  
 
GLOMERULAR FILTRATION RATE: 
 “GFR is a measure of the rate at which water and dissolved substances 
(low molecular weight, ultra filterable compounds) are filtered out of the blood 
per unit time." It provides a measure of filtering capacity of the kidneys. 
 
         Urine Concentration   X   Urine Volume  
 GFR = 
           Plasma Concentration 
 
Normal GFR, adjusted for body surface area, is 100-130 mL/min/1.73m2. 
 
 Mean GFR for Indians =95.5+/-11.6mL/min. Above 40 yrs of age, GFR 
decreases by about 0.4–1.2  mL/min/ every year. Accurate estimation of GFR in 
Indians is limited due to lack of GFR estimated equation validated for our 
population. Indians have lower normal range of GFR than western population. 
 
SERUM CREATININE: 
Serum creatinine is used for the measurement of GFR because: 
- creatinine is one of the filtration markers, whose clearance roughly equals the 
GFR. 
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- creatinine excretion is consistent among individuals and over a period of time. 
- estimation of serum creatinine is accurate and consistent among clinical 
laboratories. 
 
USES OF ESTIMATEDGLOMERULARFILTRATION RATE (eGFR): 
- An index of functioning renal mass. 
- Keeping track of changes in GFR can delineate progression of renal 
dysfunction. 
- Predicts the time of onset of Kidney failure along with the risk of 
complications. 
- Helps in proper dosing of drugs corrected to GFR to avoid potential drug 
toxicity. 
 
CKD-EPI (CKD-epidemiology collaboration group): 
- Same accuracy as that of MDRD equation at GFR < 60 mL/min/1.73m2. 
- Greater accuracy at higher GFR i.e. GFR >60mL/min./1.73m2. It reduces the 
overestimation of CKD with MDRD equation. 
- Gender, age, race & serum creatinine were included. 
- Different factors for black, white or other races with different serum creatinine 
values in both the male and female subjects. 
- Better accuracy with important applications in public health and clinical 
practice. 
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CKD-EPI (IDMS CALIBRATED) 
 eGFR=141*min (Serum Cr/K,1)α *Max (Serum Cr/K,1)-1.029 *0.993age 
*(1.018iffemale)*1.159if  black. 
 K-0.7 for female, &0.9 for Male. 
 α is -0.329 for female&-0.411 for Male, min indicates minimum of serum 
Cr/K or 1,Max-Maximumofserum Creatinine/K or 1. 
 
WHITE OR OTHER RACE (Female) 
 If serum creatinine </=0.7 
 eGFR=144*(serum Cr/0.7)-0.329*o.993Age. 
 If serum creatinine >0.7, 
 e GFR=144*(serum Cr/0.7)-1.209*0.993Age. 
 
WHITE OR OTHER RACE (MALE) 
 If serum Cr<=0.9, 
 e GFR=141*(serum Cr/0.9)-0.411*o.993Agecc 
 If serum Cr>o.9, 
 eGFR=141*(serum Cr/0.9)-1.209*0.993Age. 
 
Klotho 
 Klotho is a single pass transmembrane protein that shares sequence identity 
with family 1 β-glycosidases. Klotho gene is one, but three isoforms of Klotho 
protein exist, in the transmembrane form, a soluble form which is shed, and a 
truncated soluble form formed by alternative splicing of Klotho mRNA. The extra 
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cellular domains of Klotho KL1 and KL2 type 1 β-glycosidase can be shed from 
the surface of the cell by membrane anchored proteolytic enzymes and liberated 
into circulation(7,8). 
 
The expression of Klotho is predominantly present in proximal and distal 
renal tubules, in the parathyroid glands and choroid plexus in the brain(9). 
 
 
 
Figure 1: Schematic diagram of secreted Klotho, membrane Klotho, FGF 23 
and FGF 23 receptor. 
Courtesy: Orson W Moe. The emerging role of Klotho in clinical nephrology. 
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Figure 2: Production of various forms of klotho. 
 Courtesy : Masanobu Kawai. The FGF 23/klotho axis in the regulation of 
mineral and metabolic homeostasis. 
 
 The multifaceted protein Klotho is found in blood, urine, cerebrospinal 
fluid and plays a significant role in anti aging, energy metabolism, anti-oxidation, 
ion transport, regulation of PTH and vitamin D and antagonism of renin-
angiotensin –aldosterone system(10). 
Chronic kidney disease can be considered as a state of deficiency of 
endocrine and renal klotho. Thus it may serve as an important  early biomarker 
and a pathogenic contributor for progression and complications in  chronic kidney 
disease(11). 
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Klotho in kidney 
Soluble α Klotho functions as an autocrine or paracrine enzyme from the 
intra luminal side in the kidney to modulate transporters and ion channels. α 
Klotho modifies the Na+- phosphate co transporter(NaPi-2a)as a glucuronidase 
and the renal outer medullary K+ and TRPV5 calcium channel as a sialidase. The 
terminal sialic acid residues from the N-linked glycans on the cell surface are 
detached by sialidase activity(12). 
 
The endocytosis of transient receptor potential cation channel, subfamily 5, 
member 5(TRPV 5) and renal outer medullary potassium channel 1(ROMK1) is 
averted by secreted Klotho by modification of the N- linked glycoproteins. 
 
Moreover, α Klotho acts from the basolateral side of membrane as a 
glucuronidase modifying organic cation transport(13). 
 
The activity of insulin, insulin- like growth factor -1 and transforming 
growth factor-β1 is suppressed by secreted klotho by interacting with them or 
their receptors(14). 
 
 These enzymatic reactions are FGF 23 -independent and not attributable to 
α klotho’s function as a co receptor. 
 
The expression of α Klotho is maximal in the kidney, but it is not clear 
whether α Klotho circulating in serum is derived from the kidney. The strongest 
evidence to date, comes from renal tubule-specific partial deletion of α Klotho, 
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which causes reduced serum α Klotho levels and systemic features closely 
resembling the phenotype in global α Klotho deletion mice, indicating that the 
kidney may be the principal source of endocrine α Klotho(15,16). 
 
 The route of elimination of circulating α Klotho is less understood than its 
production. Animal experiments indicate the presence of intravenously injected 
exogenous extracellular domain of recombinant α Klotho protein in urine(17). 
Transport of circulating α Klotho into the urine is through transepithelial 
transcytosis(16), thus making circulating α Klotho to act as luminal enzyme to 
modulate target proteins(18). 
 
Thus both production and clearance of α Klotho is altered in a complex 
manner in chronic kidney disease. 
 
Type 1 transmembrane proteins can be cleaved and released by  
“A Disintegrin And Metalloproteinase” (ADAM), a metalloproteinase, which 
cleaves type I transmembrane proteins to cast off membrane anchored growth 
factors, cytokines and receptors. In the regulation of cell signaling in 
physiological and pathological conditions, ADAM plays a vital role(19). 
 
Tissue culture studies revealed that α secretase (ADAM 10/17) and β 
secretase inflect shedding of ectodomain to form soluble α Klotho protein by 
acting at two cleavage sites: adjacent to the juxtamembrane region and between 
the KL1 and KL2 domains(20). 
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α Klotho traverses across renal tubules from the basolateral to luminal side, 
indicated by its absence in Bowman’s space and by its presence in proximal 
lumen(16,21). 
 
In addition, Klotho protects the kidney from the oxidative damage(22). 
 
Klotho in CKD 
Animal studies reveal that there are striking similarities between Klotho 
deficient mice and mice with CKD. The features include hyperphosphatemia, 
elevated FGF23 levels, ectopic soft tissue calcification and diminished Klotho 
levels in the blood and kidney, suggesting that CKD might be a condition of 
Klotho deficiency(11). 
 
In CKD patients predisposing with obstructive nephropathy, rejected 
transplanted kidney, diabetic nephropathy, chronic glomerulonephritis and other 
causes, renal Klotho RNA is remarkably diminished(23). 
 
 While clinical data in human plasma Klotho is yet to be acquired, urinary 
Klotho levels of CKD patients were shown to decrease at very early stage and 
sustainably reduced with progression of CKD(18). Klotho levels in plasma, urine 
and kidney are decreased in parallel in rodent CKD models. 
 
Overexpression of Klotho improves renal function and ameliorates renal 
histology, which are associated with less superoxide anion generation and lipid 
peroxidation, and with decreased levels of cell senescence markers, mitochondrial 
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DNA fragmentation and apoptosis. Thus Klotho may serve as a reno protective 
factor by diminishing oxidative stress, cell senescence and apoptosis(24). 
 
The pathophysiological mechanisms underlying Klotho downregulation in 
CKD are more complex than just renal tissue loss. It is likely that uremic toxins and 
abnormal mineral metabolism contribute to downregulation of renal Klotho and 
subsequent decrease in blood Klotho. 
 
Aberrant mineral metabolism 
Hyperphosphatemia is a pathogenic intermediate contributing to chronic 
progression and complications in CKD. Phosphate overload inhibits Klotho 
expression in the kidney(25). Normal mice fed with high Pi diet have strikingly 
decreased Klotho protein and Klotho mRNA in the kidney, while Klotho 
hypomorphic mice fed with low Pi diet regain the expression of Klotho partially(26) 
 
Figure 3: Mechanism of downregulation of Klotho expression in CKD 
Courtesy: Hu et al. Contrib Nephrol.2013; 180:47-63. 
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Low 1,25- dihydroxy vitaminD3 may be an effect of loss of renal tissue 
and high blood FGF23 in CKD(27).Vitamin D responsive elements are found in 
human and rodent Klotho gene and administration of 1,25- dihydroxy vitaminD3 
promotes renal Klotho expression in vivo. In vitro studies point out that 1,25- 
dihydroxy vitaminD3 induces membrane and secreted forms of Klotho mRNA in 
kidney cell lines(28). 
 
Vitamin D receptor null mice have reduced renal Klotho mRNA 
expression, indicating that an interplaying network of vitamin D, phosphate and 
FGF 23 leading to Klotho production exists(29). 
 
Uremic toxin 
Indoxyl sulfate, a uremic toxin which accumulates in the blood in CKD, 
likely promotes progression and cardiovascular disease in CKD and suppresses 
renal Klotho mRNA in Dahl salt – resistant normotensive and hypertensive rats 
and induces tubulointerstitial fibrosis and increases cell senescence in renal 
tubular cells of Dhal salt- resistant hypertensive rats. Indoxyl sulfate may 
downregulate renal Klotho in CKD through stimulation of oxidative pathways and 
NF-κB(30). 
 
Renin- angiotensin- aldosterone(RAA) system 
Angiotensin II and aldosterone suppress Klotho expression in the kidney 
and kidney cell lines(31). 
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It was put forward that angiotensin II – induced oxidative stress leads to 
downregulation of Klotho expression, because free radical scavenging averts 
depletion of Klotho by both oxidative stress and angiotensin II infusion. The 
intercommunication between RAA activation, phosphate and the vitamin D – 
FGF 23 axis intensifies downregulation of Klotho expression in CKD(31). 
 
Klotho’s rolein progression of chronic kidney disease 
Deficiency of Klotho is not only a trivial biomarker for CKD but 
contributing factor for CKD development, progression and complications(11). 
 
Render renal tissues more vulnerable to injury 
Cell ageing induced by Klotho deficiency is attributed by up-regulation of 
Wnt signal activity. The intracellular Klotho abolishes cell senescence by 
inhibiting retinoic acid –inducible gene 1 activated expression of IL-6 and IL-8 in 
vitro and in vivo(24). 
 
Klotho deficiency in CKD would augment cell senescence caused by 
oxidative stress and accelerated senescence eventually leads to apoptosis. 
Reduction in stem cells might decline the kidney’s ability to check against renal 
insults and impair   regeneration(32). 
 
Promote renal fibrogenesis 
Renal fibrosis is a prominent histological feature in CKD and presumably 
plays a part in chronic progression; and TGF – β is a key player in renal 
fibrosis(33). Klotho attenuates renal fibrosis by inhibiting the action of TGF- β1 on 
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type IITGF- β receptor. TGF-β1 – induced Smad II phosphorylation is suppressed 
by klotho in rat tubular epithelial cell line, putting forward that Klotho protein 
inhibits fibrosis mainly by inhibiting TGF- β1 signaling(34). 
 
Contributions of Klotho deficiency to complications of chronic kidney disease 
Deficient Klotho not only aggravates renal disease but also exacerbates 
extra renal complications in CKD 
 
Ectopic calcification: 
 Extensive ectopic calcification in soft tissue observed in Klotho deficient 
mice is also noticed in CKD subjects, suggesting a possible pathogenic 
interrelation between Klotho deficiency and calcification. Amplification of Klotho 
by supplementation or genetic manipulation markedly inhibits vascular 
calcification in CKD animals(35). 
 
Elevated plasma Pi correlates with vascular calcification in CKD and 
multiple pathogenic roles of high Pi have been proposed to induce or exacerbate 
vascular calcification. High ambient Pi induces vascular smooth muscle cells 
reprogramming to a phenotype resembling osteoblast and osteochondrocytein a 
type 3 Na + coupled transporters (Pit1 and Pit2) dependent manner(36). 
 
 High Pi causes cell apoptosis and consequent vesicle release for deposition 
on matrix. Klotho suppress this reprogramming caused by high Pi in rat cell lines 
in vitro(37). Klotho also plays as an anti- inflammatory mediator in vascular 
endothelial cells and smooth muscle cells. 
26 
 
 
 
 
 
Figure 4: Pathogenic role of Klotho deficiency. 
Courtesy: Hu et al. Contrib Nephrol.2013; 180:47-63. 
 
 Osteogenic/chondrogenic trans – differentiation of vascular smooth muscle 
cells under the influence of uremic environment including high Pi fails to respond 
to FGF23(32). Extremely high FGF23 exerting  pathological activity via 
stimulation of off-target genes to bring about vascular calcification in the 
background of low blood Klotho is one more probability(18). 
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Uremic cardiomyopathy 
 Cardiac hypertrophy, particularly left ventricular hypertrophy, is often 
encountered in CKD patients. Apart from common risk factors, novel factors 
including activated RAA system, vitamin D deficiency, high FGF 
23concentrationand low Klotho concentration are involved in causing 
cardiomyopathy of CKD(38). 
 
 Klotho is expressed in the heart exclusively at the sinoatrial node. 
 
Secondary hyperparathyroidism 
Apart from abnormal mineral metabolism (Pi, Ca and vitamin D), high 
FGF23 and low Klotho contribute to secondary hyperparathyroidism. The plasma 
level and activity of FGF23 is raised and FGFR1 and Klotho expression is 
reduced in parathyroid glands of CKD patients(39). 
 
Under physiological milieu with normal Klotho and FGFR expression, 
FGF23 reduces PTH production, raises parathyroid calcium –sensing receptor and 
the vitamin D receptor expression and suppression of cell proliferation. In the 
uremic milieu with decreased Klotho and FGFR1 expression in parathyroid 
glands, FGF23 no longer exerts its inhibitory effect on the gland and fails to raise 
calcium sensing receptor and vitamin D receptor(40). 
 
Fibroblast growth factor 23 
FGF 23 is a protein encoded by the FGF23 gene on chromosome 12p13.3 
incorporating 251 aminoacids(41). “After cleavage of the native protein the signal 
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sequence containing 24 aminoacids and O-glycosylation by UDP-N-acetyl-alpha-
D-galactosamine: polypeptide N-acetyl galactosaminyl transferase 3 (GALNT3), 
the mature protein, FGF23 (25-251), is secreted into the circulation”(42,43). 
 
FGF23 is deficient in heparan-sulfate (HS) binding -motifs, which reduces 
the affinity of matrix binding and facilitates the ligand to function in an endocrine 
way(44). 
 
Four specific genes encode FGF receptors (FGFR1-FGFR4). All the four 
receptors share an almost identical domain structure. The three immunoglobulin –
like domains (D1-D3) form the extracellular domain, followed by a single pass 
transmembrane domain and an intracellular domain possessing tyrosine kinase 
activity(45). 
 
Studies reveal that in all the three FGF 19 subfamily members, an 
important residue for FGFR binding is replaced, so these FGFs have intrinsically 
reduced affinity for their cognate receptors. Decreased receptor binding affinity 
along with the low HS binding affinity of these FGFs is the mechanism behind the 
dependence of these ligands on Klotho proteins to act in their target tissues(45). 
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Figure 5: Structure of FGF 23 and its cleavage site. 
 
Courtesy : Masanobu Kawai. The FGF 23/Klotho axis in the regulation of mineral 
and metabolic homeostasis. 
 
 FGF23 depends on Klotho as a coreceptor. “Immuno-precipitation 
experiments, surface plasmon resonance (SPR) spectroscopy and functional 
assays measuring the mitogenic response of BaF3 cells or activation of the 
MAPK-pathway in HEK293 cells have shown that Klotho forms a ternary 
complex with FGF23and either FGFR1c, FGFR2c, FGFR3c or FGFR4”(46). 
 
Studies in literature using neutralizing ant-iFGF23 antibodies point out that 
the N-terminal portion ofFGF23 interacts with FGFR1c, while the C- terminus 
binds to Klotho and both these aspects of intercommunication are crucial for 
bioactivity in vitro and in vivo(47). 
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A study using mice with kidney specific deletion of FGFR1 demonstrates 
that FGFR1 modulates the phosphaturic effects of FGF23(48). 
 
FGF23 utilizes a non-canonical signal transduction pathway at the 
proximal tubules or it promotes the secretion of an intermediary phosphatonin in 
the distal tubule, which has its effects in a paracrine mode on the proximal 
tubules(49). 
 
 Phosphate and vitamin D metabolism is influenced byFGF23, a member of 
the fibroblast growth factor family. FGF 23 is a bone derived hormone produced 
by osteoblasts and osteocytes in response to vitamin D and raised phosphate. FGF 
23 is basically a phosphaturic hormone, controlling apical membrane type 2 a 
sodium – phosphate cotransporters in proximal tubules by acting through FGF 
receptors and the coreceptor Klotho. 
 
 
Figure 6: Endocrine regulation of phosphate homeostasis. 
Courtesy : John et al. Am J Kidney Dis.2011 July; 58(1):127-134 
31 
 
 
1. PTH stimulates vitamin D synthesis. 
2. Vitamin D by negative feedback decreases PTH. 
3. FGF23 reduces vitamin D synthesis. 
4. Vitamin D increases FGF 23 expression in bone by negative feedback. 
5. FGF 23 reduces PTH synthesis. 
6. PTH increases FGF 23 expression by negative feedback. 
 
1 α-hydroxylase expression is suppressed by FGF 23 and thus the synthesis 
of the active vitamin D hormone is decreased. It also stimulates the catabolic 24- 
hydroxylase and inhibits parathyroid hormone secretion(50). 
 
Healthy individuals are maintaining their serum phosphate in a narrow 
range because FGF23 levels adjust in parallel with the amount of dietary 
phosphate intake. FGF23 levels increase in feedback to high phosphate intake, 
promoting greater urinary fractional excretion of phosphate and by lowering 1,25-
dihydroxyvitamin D levels, thus reducing the efficiency of intestinal phosphate 
absorption(51). 
 
A classic negative feedback loop exists between vitamin D and FGF 23, 
thus 1,25-dihydroxy vitamin D stimulates FGF 23 secretion and FGF 23 
suppresses the levels of 1,25-dihydroxy vitamin D(52). FGF 23 transcription is 
regulated by vitamin D response element in the FGF 23 promoter site in such a 
way that some amount of vitamin D activity is essential for FGF 23production(53). 
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The serum phosphate levels are determined by the balance between 
absorption of phosphate in the intestine from the diet, storage in the skeleton and 
excretion through urine. 
 
Phosphate reabsorption from the urine in the proximal renal tubules via 
type 2 and type 3 sodium phosphate co-transporters plays a significant role. Renal 
phosphate reabsorption is under tight hormonal regulation by parathyroid 
hormone and fibroblast growth factor 23. 
 
FGF 23and mortality 
Elevated FGF 23 levels were independently correlated with higher risk of 
mortality(54). Kidney transplant recipients with raised FGF 23 levels were 
associated with greater risk of mortality, allograft loss and their composite(55). 
 
FGF 23 and progression of CKD  
Elevated FGF 23 is a potentially significant risk factor for ESRD(56). 
 
FGF 23 and cardiovascular disease events 
Elevated FGF 23was associated with greater risk of myocardial infarction, 
stroke,  coronary, carotid or lower limb revascularization, amputation and 
death(57). 
 
Therapeutic strategies to lower FGF 23 levels 
Reducing dietary phosphate intake lowers FGF 23 levels in healthy 
individuals(58). In a randomized control trial, assignment of a 750-mg phosphate 
diet did not significantly lower FGF 23 levels but the 1500 mg diet raised FGF 23 
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levels in a considerable number of participants, putting forward that dietary 
phosphate ingestion contributes to dynamic changes in FGF 23 levels in CKD(59). 
 
Administration of phosphate binders such as lanthanum, sevelamer and 
aluminium – magnesium lowered FGF 23 levels in healthy subjects, 
hyperphosphatemic ESRD patients and CKD patients with phosphate levels 
normal or elevated(60,61). 
 
FGF 23 in bone: 
Fibroblast growth factor 23 has physiologically significant functions in 
bone on bone mineralization and on hematopoiesis(62). FGF 23 is a strong 
suppressor of tissue non-specific alkaline phosphatase (TNAP) mRNA 
transcriptionin bone in a Klotho independent manner. TNAP is a key factor for the 
regulation of bone mineralization by cleaving the mineralization inhibitor 
pyrophosphate synthesized by osteoblasts to prevent premature mineralization of 
osteoid(63). 
 
Parathyroid cell resistance to fibroblast growth factor 23 in secondary 
hyperparathyroidism of chronic kidney disease: 
FGF 23 exerts its action on the parathyroid through its receptor, Klotho-
FGFR1c, to activate the MAPK pathway and lower PTH expression. High levels 
of both FGF 23 and PTH are observed in CKD. In CKD there is decreased 
expression of parathyroid gland Klotho and FGFR1 mRNA and these changes 
contribute to the resistance of the parathyroid to high levels of FGF 23(64,65). 
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Calcium and phosphate homeostasis in chronic kidney disease 
Calcium and phosphate are crucial for normal cardiovascular and 
neuromuscular function and for many enzyme mediated and cellular signaling 
activity. Calcium and phosphate provide structural framework to the skeleton, 
which is the primary storehouse of mineral ions in the body(66). 
 
When the concentration of ionized calcium decreases, parathyroid hormone 
stimulates release of calcium from skeletal reserves and stimulates conversion of 
25-hydroxy vitamin D to biologically active1,25- dihydroxy vitamin D, which 
enhances gastrointestinal calcium absorption(66). 
 
 Resorption of bone mediated by PTH releases phosphate into the 
extracellular fluid. Excessive phosphate in circulation is excreted by the kidney in 
urine in response to PTH and fibroblast growth factor 23 acting on FGF receptor-
Klotho co-receptor complexes(67). 
 
“As part of an intricate set of feedback loops that tightly regulate calcium 
and phosphate homeostasis, both PTH and1,25-dihydroxy vitamin D stimulate 
FGF23 secretionandFGF23 is the primary negative regulator of 1,25- dihydroxy 
vitamin D production”(66). 
 
There is an interruption of calcium and phosphate homeostasis early in the 
course of chronic kidney disease. 
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Human and animal data suggest  increased FGF23 level is the earliest 
detectable alteration(68). Rising FGF23 levels suppress renal production of 1,25- 
dihydroxy vitamin D, which reduces Klotho expression.  
 
 
Figure 7: Proposed therapeutic strategies in CKD 
                       Courtesy: Hu et al. Contrib Nephrol.2013; 180:47-63. 
 
Responding to the decrease in ionized calcium concentration due to 
inefficient gastrointestinal calcium absorption, the parathyroid glands stimulate 
PTH secretion, which is augmented by the release of the glands from feedback 
control by reduced 1,25-dihydroxy vitamin D levels(69). Secondary 
hyperparathyroidism resulting in constitutive bone resorption plays a major role in 
bone disease in CKD(70). 
 
PTH rises in CKD as a secondary response to calcium depletion and FGF 
23 rises as a secondary response to phosphate retention(71). 
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Healthy kidney excretes approximately two thirds of the dietary phosphate 
load and even with declining kidney function in CKD, this excretion is 
comparatively well maintained. 
 
The serum phosphate concentrations were found to be in the normal range 
until a GFR of 30 mL/min; on further decrease of GFR the phosphate levels begin 
to rise beyond the upper normal range and are found to become inversely related 
to GFR, while it is still unclear when serum phosphate levels tend to rise “within” 
the normal range in CKD(72). 
 
Serum phosphate levels above 3.5 mg/dL have already been proved to be 
significantly associated with mortality. Mortality risk progressively increased with 
each 0.5-mg/dL rise in phosphate serum levels(73). 
 
There is delayed onset of hyperphosphatemia in CKD probably due to 
counter regulatory actions of FGF 23 and PTH. Both the hormones cause 
phosphaturia when elevated and apparently stimulated as early as in CKD stage 3, 
corresponding to vitamin D status and dietary phosphate intake. 
 
Rise in serum FGF 23 levels was analogues to rise in renal fractional 
phosphate excretion, counterchecking increase in phosphate retention and 
subsequent  hyperphosphatemia(74). 
 
The positive phosphate balance brings about an osteocyte “phosphate 
sensor” communicating the release of FGF 23. PTH and FGF 23 production as 
well as release are directly interconnected. FGF 23 suppresses PTH release via 
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stimulating the dimeric Klotho/FGF 23 – receptor at the parathyroid gland. PTH 
may vice versa inhibit FGF 23 secretion from the osteocyte(72). 
 
Under normal physiological condition, metabolism of calcium is regulated 
through hormones in a three – tissue axis of intestine, kidney and bone to maintain 
serum ionized calcium within a narrow range. 
 
The maintenance of serum phosphate within normal limits in early stage 
CKD is not the physiological fact because it is maintained within normal limits at 
the expense of PTH increase(75).Variation in serum levels is a late stage 
consequence of a reduction in urinary total excretion as renal function declines, 
when the mechanism is no longer compensated by the increase of FEP induced by 
PTH(76). 
 
Serum calcium levels are involved in hyperparathyroidism progression but 
play an important role in the late stages when calcium begins to decrease(76). 
 
The two chief hormones involved are 1,25- vitaminD /calcitriol and PTH. 
Low serum ionized calcium is sensed by calcium sensing receptors on the 
parathyroid gland which in turn stimulates PTH synthesis and secretion. 
 
  
  
 
 
Aim of the study 
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AIM OF THE STUDY 
 
 To estimate the level of serum soluble α Klotho and FGF 23 levels in CKD 
patients.  
 To establish its role in chronic kidney disease - mineral bone disease. 
 
  
Materials and Methods 
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MATERIALS AND METHODS 
 
STUDY CENTRE 
 The study was carried out during the period April 2017 – August 2017 at 
Madras Medical College and Rajiv Gandhi government general hospital at the 
following departments 
 
 Institute of Biochemistry 
 Institute of Nephrology 
 
 This is a Case Control study and was conducted after getting clearance 
from the institutional ethics committee. 
 
GROUP A: 
 60 unrelated individuals diagnosed with CKD (KDOQI guidelines) 
attending the outpatient department of nephrology were included in the study after 
getting informed consent. 
 
Inclusion criteria 
 Eligible CKD patients who gave informed consent, Age 15-60 yrs on 
conservative therapy 
 
Exclusion criteria 
 Acute kidney disease, patients on renal replacement therapy 
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GROUP B:  
 30 age-and-sex-matched healthy subjects who were employees in the 
institution and attendants accompanying the patients were included in the study 
after obtaining informed consent.  
 
Inclusion criteria 
 Healthy subjects with normal renal function and no evidence of acute or 
chronic underlying illness. 
 
Methodology:  
 Serum Urea-spectrophotometric method 
 Serum Creatinine-spectrophotometric method 
 Serum Calcium-spectrophotometric method 
 Serum Phosphate-spectrophotometric method 
 Serum FGF 23-ELISA 
 Serum Soluble α klotho-ELISA 
 Serum PTH-ECLIA 
 Spot urine protein creatinine ratio-spectrophotometric method 
 
Sample size 
 Group A- CKD patients -60, 
 Group B- Healthy subjects -30 
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Serum soluble α Klotho estimation by ELISA 
Test principle 
 The kit employs a double antibody sandwich enzyme linked 
immunosorbent assay (ELISA) to assess the level of human Klotho in samples. 
Add Klotho to monoclonal antibody enzyme well which is pre-coated with human 
Klotho monoclonal antibody; incubate ; then, add Klotho antibodies labeled with 
biotin and combined with streptavidin – HRP to form immune complex; then 
carry out incubation and washing again to remove the uncombined enzyme. Then 
add chromogen solution A, B. The color of the liquid changes into blue and at the 
effect of acid, the color finally becomes yellow. The color and the concentration 
of the human substance Klotho were positively correlated. 
 
Sample collection and storage: 
 Blood samples were collected, allowed to clot for 20 minutes at room 
temperature. The tube is then centrifuged for 20 minutes at 3000 rpm. Tubes are 
then taken out and serum separated and aliquoted into 4 aliquots. Sample is stored 
at – 20ͦ C.  
 
Assay procedure 
 Kit is taken out from the 2-8 ͦ environment and kept at ambient temperature 
for 30 minutes. 
 
  
42 
 
Standard dilution 
12 ng/mL Standard No. 5 120μL original standard + 120μL standard diluents 
6 ng/mL Standard No. 4 120μL Standard No.5 + 120μL standard diluents 
3 ng/mL Standard No. 3 120μL Standard No.4 + 120μL standard diluents 
1.5 ng/mL Standard No. 2 120μL Standard No.3 + 120μL standard diluents 
0.75 ng/mL Standard No. 1 120μL Standard No.2 + 120μL standard diluents 
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Injection of samples: 
 Blank well: Do not add samples and Klotho antibody labeled with biotin, 
streptavidin- HRP; only chromogen solution A, B and stop solution are 
added. 
 Standard wells: add standard 50μL, streptavidin – HRP 50μL (since the 
standard already has combined biotin antibody, it is not necessary to add 
the antibody) 
 Test well: Add sample 40μL and then add both Klotho antibody 10μL and 
streptavidin – HRP 50μL.  
 Seal the plate with sealing membrane for gentle shaking. The plate is then 
incubated at 37 ͦ C for I hour. 
 Wash solution preparation: dilute 30 times the wash concentrate with 
distilled water. 
 
Wash procedure: 
 The plate is removed from the incubator, membrane is carefully removed 
and the liquid is carefully drained from the plate. 
 The plate is washed using an automated washer. 
 Then add chromogen solution A 50μL, then chromogen solution B 50μL to 
each well. 
 Incubate for 10 minutes away from light. 
 Add stop solution 50μL into each well to arrest the reaction (the blue 
changes into yellow immediately) 
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Final measurement: 
 Take blank well as zero, measure the optical density under 450 nm 
wavelength, which is carried out within 15 minutes after adding the stop solution. 
 
Serum Fibroblast growth factor 23 estimation by ELISA 
Test principle: 
 The kit employs a double antibody sandwich enzyme linked 
immunosorbentassay (ELISA) to assay the level of Human fibroblast growth 
factor- 23 in samples. Add fibroblast growth factor 23 to monoclonal antibody 
enzyme well which is pre coated with human fibroblast growth factor 23 
monoclonal antibody; incubate; then add fibroblast growth factor 23 antibodies 
labeled with biotin and combined with streptavidin – HRP to form immune 
complex; then carry out incubation and washing again to remove the uncombined 
enzyme. Then add chromogen solution A,B, the color of the liquid changes into 
blue, at the effect of acid, the colour finally becomes yellow. The chroma of color 
and the concentration of the human substance fibroblast growth factor – 23 of 
sample were positively correlated. 
 
Sample collection and storage: 
 Samples are collected and are allowed to clot for 20 minutes at room 
temperature. The tube is then centrifuged for 20 minutes at 3000 rpm. Tubes are 
then taken out and serum separated and aliquot into 4 aliquots. Sample is stored at 
– 20 ͦ C. 
 
45 
 
Assay procedure 
 Kit is taken out from the 2-8 ͦ C storage and kept at ambient temperature for 
30 minutes. 
 
Standard dilution: 
800pg/mL Standard No.5 120μL original standard + 120μL standard diluents 
400pg/mL Standard No.4 120μL standard No.5 + 120μL standard diluents 
200pg/mL Standard No.3 120μL standard No.4 + 120μL standard diluent 
100pg/mL Standard No.2 120μL standard No.3 + 120μL standard diluents 
50pg/mL Standard No.1 120μL standard No.2 + 120μL standard diluents 
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Injection of samples: 
 Blank well:  Do not add samples and FGF-23 antibody labeled with 
biotin, streptavidin- HRP, only chromogen solution A, B and stop solution 
are added. 
 
 Standard wells: Add standard 50μL, streptavidin – HRP 50μL (since the 
standard already has combined biotin antibody, it is not necessary to add 
the antibody) 
 
 Test wells: Add sample 40μL and then add both FGF-23 antibody 10μL 
and streptavidin – HRP 50μL.  
 
 Seal the plate with sealing membrane for gentle shaking. The plate is then 
incubated at 37 ͦC for I hour. 
 
 Wash solution preparation: dilute 30 times the wash concentrate with 
distilled water. 
 
Wash procedure: 
 The plate is removed from the incubator, membrane is carefully removed 
and the liquid is carefully drained from the plate. 
 The plate is washed using an automated washer. 
 Then add chromogen solution A 50μL, then chromogen solution B 50μL to 
each well. 
 Incubate for 10 minutes away from light. 
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 Add stop solution 50μL into each well to arrest the reaction (the blue 
changes into yellow immediately) 
 
Final measurement: 
 Take blank well as zero, measure the optical density under 450 nm   is 
carried out within 15 minutes after adding the stop solution. 
 
Creatinine estimation: 
Method: Jaffe‘s kinetic method (using IDMS traceable calibrator) 
 
Principle: In alkaline environment, creatinine forms a yellow –orange complex 
with picrate. The rate of formation of coloured complex is proportional to the 
creatinine concentration in the specimen. The assay uses rate blanking to 
minimize interference by bilirubin. To correct for non-specific reaction caused by 
serum/plasma pseudo-creatinine chromogens, including proteins and ketones, the 
results are corrected by (-0.3mg/dL). 
 
 Creatinine + picric acid    yellow orange complex 
 
Reagents: 
R1 – potassium hydroxide900mmol/L; phosphate 135 mmol/L 
R2- picric acid 38mmol/L; non reactive buffer 
 
Reference range: 0.5 to 1.3 mg/dL 
 
 
 
Alkaline pH 
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Urea estimation: 
Method: Kinetic method with urease and glutamate dehydrogenase. 
Principle: Urea is hydrolyzed by urease to form ammonium and carbonate. 
                                          
                                       urease 
 Urea + 2H2O                          2NH4+ +  CO32 
   
In the second reaction 2-oxoglutarate reacts with ammonium in the 
presence of glutamate dehydrogenase (GLDH) and the coenzyme NADH to 
produce L-glutamate. In this reaction two moles of NADH are oxidized to NAD+ 
for each mole of urea hydrolyzed. 
    Glutamate dehydrogenase 
NH4++ 2-oxoglutarate+ NADH    L- glutamate + NAD+ + H2O 
 
The rate of decrease in the NADH concentration is directly proportional to the 
urea concentration in the specimen and is measured photometrically.  
Reagents: 
R1 – NaCl 9% 
R2 – TRIS buffer 220 mmol/L; 2-oxoglutarate 73mmol/L; NADH 2.5 mmol/L; 
ADP 6.5 mmol/L; urease –jackbean; GLDH >80μkat/L 
Reference range: 15 to 40 mg/dL 
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Calcium estimation: 
Method: Arsenazo III  
Principle: Arsenazo III combines with calcium ions at pH 6.5 to form a colored 
chromophore, the absorbance of which is measured at 650 nm and is proportional 
to calcium concentration. 
 Reagents : 
Arsenazo III 0.20 mmol/L; buffer pH 6.75-100mmol/L 
Reference range: 8.6 to 10.2 mg/dL 
 
Phosphate estimation: 
Method: Molybdate UV method 
Principle: Inorganic phosphate combines with ammonium molybdate in the 
presence of strong acid (H2SO4) to form phosphomolybdate. The formation of 
reduced phosphomolybdate is measured at 340 nm and is directly proportional to 
the inorganic phosphate present in the sample.  
Phosphate  +   ammonium                              ammonium phosphomolybdate 
 Reagents:  
R1 – sulfuric acid 0.36 mol/L 
R2- ammonium molybdate 3.5 mmol/L; sodium chloride 150 mmol/L 
Reference range: 2.5 to 4.5 mg/dL 
 
 
 
50 
 
Parathyroid hormone estimation: 
 The biologically active N –terminal fragment has a half of only few 
minutes. Selective measurement of the intact parathyroid hormone allows direct 
ascertainment of the secretary activity of the parathyroid glands. 
 
Method: ECLIA 
Principle: The assay employs a sandwich test principle in which a biotinylated 
monoclonal antibody reacts with the N – terminal fragment (1-37) and a 
monoclonal antibody labeled with a ruthenium complex reacts with the c-terminal 
fragment. 
The antibodies used in the assay are reactive with epitopes in the amino acid 
regions 26-32 and 37-42. 
Reagents: 
M – streptavidin coated microparticles 0.72mg/mL 
      R1-biotinylated monoclonal anti- PTH antibody (mouse) 
R2-monoclonal anti PTH antibody (mouse) labeled with ruthenium 
complex. 
Reference range: 10 to 65 pg/mL  
 
Urine protein creatinine ratio estimation: 
 Spot protein creatinine ratio was performed in the urine of subjects. 
 Urine protein estimated by using pyrogalol red method. 
 Urine creatinine estimated by Jaffe’s method. 
Statistical Analysis 
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STATISTICAL ANALYSIS 
 
 Data was analyzed using  SPSS software 20.00 version and P value less 
than 0.05 was considered significant and less than 0.001 highly significant. 
 
 Chi square test was used for analysis of gender 
 
 Student t-test was used for analysis of age, Klotho, FGF23, PTH, 
creatinine, urea, calcium, phosphate and urine PCR 
 
 Correlation of parameters between Klotho and FGF 23, eGFR and Klotho 
and eGFR and FGF 23 were analyzed by Pearson correlation analysis. 
 
 ROC curves for Klotho and FGF23 were plotted using SPSS software. 
 
 Multiple regression analysis was performed to evaluate relationship 
between eGFR and other parameters (Klotho, FGF23, creatinine, urea, 
PTH, calcium, phosphate and urine PCR) 
 
  
Results 
  
S.NO AGE SEX
KLOTHO 
(ng/mL)
FGF 23 (pg/mL)
CREATININE 
(mg/dL)
UREA 
(mg/dL)
eGFR
CALCIUM 
(mg/dL)
PHOSPHATE 
(mg/dL)
PTH 
(pg/mL)
PCR DIAGNOSIS
1 52 M 1.42 647 12.3 178 5 5.2 7 350 1.1 SHT
2 53 M 1.12 598 10.5 124 6 8.1 5.9 124 3.1 DM/CAD
3 55 M 1.58 526 7.2 116 9 6.2 3.6 197 0.4 DM/SHT
4 53 M 2.08 402 6.8 123 10 7.1 3.4 123 6.3 DM/SHT
5 50 M 1.9 711 6.1 106 11 7.8 3.9 177 1.6 SHT
6 53 F 2.03 552 5 64 11 7.8 6.4 236 0.58 DM
7 60 f 3.53 408 4.5 96 12 8.4 5.4 135 2 DM/SHT
8 47 M 2.29 336 5.6 62 13 8.6 3.1 73 0.82 PT
9 50 M 3.67 452 4.8 87 15 8.2 3.8 25 1.1 SHT/SNAKE BITE
10 61 F 2.14 402 3.6 69 15 7.6 4.5 134 0.55 SHT
11 62 F 4.36 270 3.5 107 15 6.9 4.6 417 6.6 DM/SHT
12 50 M 3.29 492 4.8 81 15 9 3.7 89 4.9 CIN
13 52 F 5.04 294 3.4 65 17 9.4 4.6 65 2 DM/SHT
14 40 F 3.07 950 3.7 122 17 7.6 7.1 626 6.2 DM/SHT
15 30 M 3.97 380 4.7 76 18 7.6 4 181 1.9 SHT
16 64 F 5.38 264 3.1 90 18 8.3 3.8 90 0.05 HT/CIN/MN
17 45 F 3.29 505 3.4 95 18 7.4 3.7 275 0.73 DM
18 60 M 2.49 379 4 82 18 7.3 4.7 126 13.3 DM/SHT
19 55 M 2.73 322 3.9 75 19 8.2 2.1 75 6.2 DM/SHT
20 39 M 2.32 511 3.5 29 24 8.7 3.2 42 0.8 YOUNG STROKE/HT
21 54 M 3.49 225 3.1 60 25 7.8 4.3 60 9.6 DM/SHT
22 60 F 2.36 370 2.4 53 25 7.6 4 62 5.7 SHT/CIN
23 38 F 3.71 281 2.3 51 30 8.9 4.2 51 0.54 SHT
24 65 M 2.29 520 2.5 79 30 9 2.8 103 1.3 DM/SHT
25 55 F 1.86 573 2.1 33 30 7.1 2.2 340 0.45 DM/SHT
26 45 M 3.38 241 2.6 91 33 7.3 5.9 29 0.89 DM
27 75 M 3.04 272 2.2 77 33 9.2 3.3 10 0.79 DM
28 68 M 7.49 225 2.3 52 33 7.3 2.8 52 0.6 SHT
29 49 M 3.06 261 2.5 59 34 8.5 2.7 53 0.81 DM/SHT
30 54 M 3.27 233 2.2 38 38 7.4 2 45 2.3 IGA NEP
31 58 F 0.985 278 1.7 39 38 10.4 4.7 88 4.6 DM
32 61 F 5.55 374 1.5 47 40 8.2 2.9 44 0.08 DM / HYPOTHYROIDISM
MASTER CHART  -  CASES CKD
S.NO AGE SEX
KLOTHO 
(ng/mL)
FGF 23 (pg/mL)
CREATININE 
(mg/dL)
UREA 
(mg/dL)
eGFR
CALCIUM 
(mg/dL)
PHOSPHATE 
(mg/dL)
PTH 
(pg/mL)
PCR DIAGNOSIS
33 47 F 3.71 298 1.7 51 41 9 3.7 35 0.03 DM/SHT
34 25 M 3.82 236 2.4 33 42 8.9 1.6 26 0.62 IGA NEP
35 35 F 3.28 277 1.8 35 42 8.5 2.6 25 2.6 SHT
36 54 F 3.78 309 1.6 38 42 9 4 55 0.66 DM/FSGS
37 74 F 1.12 588 1.4 60 43 7.9 4.2 94 0.75 SHT
38 63 M 3.18 185 1.9 25 43 7 2.5 130 0.9 DM/SHT
39 52 F 4.34 155 1.5 40 46 8.2 3 27 0.04 CIN
40 52 F 5.09 363 1.4 35 50 9.4 3.3 33 6.1 DM/SHT
41 58 M 2.26 230 1.7 46 50 7.6 3.5 13 1.3 DM
42 70 F 1.72 214 1.2 27 53 8.6 3 44 1.3 DM
43 44 M 2.16 242 1.7 69 56 8.4 3.4 38 0.11 SHT
44 57 F 3.69 222 1.1 28 65 8.9 3 41 0.59 DM/SHT
45 55 F 4.78 211 1.1 32 65 10.6 4.5 23 0.79 ANALGESIC ABUSE
46 18 M 4.11 224 1.7 40 67 10 3.9 25 0.03 ATN/CKD/POISONING
47 60 M 3.62 192 1.3 34 69 10.5 4.1 34 0.54 SHT
48 30 F 3.31 237 1.2 32 70 7.9 3.2 17 0.04 IGA NEP
49 65 M 6.2 267 1.2 24 73 8.4 3.1 24 0.13 DM
50 42 M 3.44 302 1.3 34 78 10.9 3.5 11 0.03 DM
51 42 M 5.18 280 1.3 42 78 8.2 2.3 17 5.1 DM/SHT/IGA
52 52 M 3.72 182 1.2 29 80 8.6 2.8 32 0.9 DM/SHT
53 40 F 6.85 274 1 20 82 8.1 2.6 20 9.1 DN / HYPOTHYROIDISM
54 67 F 3.97 233 0.8 25 88 8.8 3.1 32 0.82 DM/SHT
55 47 M 3.37 230 1.1 20 92 9.5 2.8 21 0.03 IGA NEP
56 42 M 3.29 146 1.1 34 95 8.7 2.7 42 8.09 SHT
57 49 F 4.72 231 0.8 27 100 8.7 3.6 15.2 0.03 DM
58 65 M 1.62 261 0.8 32 109 9.5 3.5 17 0.03 DM
59 48 M 2.8 202 0.9 18 117 8.3 2.8 12 0.03 DM/SHT
60 35 F 2.31 185 0.7 18 130 7.9 3.1 9 1.9 IGA NEP
S.NO AGE SEX
KLOTHO 
(ng/mL)
FGF 23 
(pg/mL)
CREATININE 
(mg/dL)
UREA 
(mg/dL)
eGFR
CALCIUM 
(mg/dL)
PHOSPHATE 
(mg/dL)
PTH 
(pg/mL)
PCR
1 42 F 5.9 239 0.6 28 130 10.3 3.1 20 0.02
2 77 F 3.46 297 0.8 32 82 10.1 3 28 0.08
3 72 M 11.39 189 0.8 19 103 10 3.5 55 0.08
4 58 M 4.97 217 1.3 38 70 9.3 3.2 28 0.06
5 43 M 9.53 206 1 35 106 9.4 3.7 16 0.03
6 53 M 8.03 207 0.8 28 118 10.1 3.8 23 0.05
7 57 M 4.13 268 1 42 96 9.1 3.7 41 0.08
8 53 F 8.26 202 0.8 14 98 10 4.2 35 0.19
9 42 F 6.02 260 0.7 18 124 9.5 3.6 34 0.18
10 45 F 5.28 238 0.9 12 89 9 3.6 27 0.04
11 55 M 4.34 227 1 28 98 9.5 3.6 45 0.06
12 60 M 3.8 246 0.9 32 107 9.8 3.2 44 0.07
13 55 M 11.41 142 0.7 37 123 10 3.9 20 0.06
14 43 F 6.34 204 0.6 20 129 9 4.1 30 0.13
15 62 M 4.19 166 0.6 29 125 9.3 4.1 49 0.1
16 55 M 5.31 111 0.7 26 123 9.3 3.2 17 0.05
17 43 M 6.17 258 0.7 22 134 8.9 4.1 15 0.08
18 57 M 4.24 241 0.7 41 121 8.6 3.9 15 0.07
19 55 M 4.19 243 0.8 31 117 9.7 3.7 17 0.06
20 54 F 4.44 239 1 28 74 9.9 3.7 23 0.13
21 52 M 4.35 226 0.8 35 119 9.7 2.9 7 0.19
22 57 M 4.55 255 0.8 27 115 9.1 4 5 0.01
23 60 M 3.87 242 0.7 31 119 8 3 27 0.23
24 54 M 4 229 0.8 30 117 7.7 2.4 23 0.06
25 50 F 5.46 234 0.4 22 141 7.1 3.1 20 0.04
26 43 F 5.62 198 0.7 26 123 9 3.4 28 0.13
27 45 F 3.76 221 0.5 18 135 8.6 3.9 22 0.11
28 55 F 5.66 226 0.5 32 126 11.4 3.7 12 0.02
29 41 M 5.57 225 0.6 30 145 8.9 2.8 21 0.1
30 38 F 4.14 194 0.5 23 142 9.6 2.9 18 0.08
MASTER CHART  -  CONTROLS
52 
 
RESULTS 
 
TABLE 1: GENDER WISE DISTRIBUTION OF STUDY GROUP AND 
CONTROL GROUP 
Gender 
GROUP 
CASES CONTROLS 
Number Percentage Number Percentage 
Male 33 55.00 18 60.00 
Female 27 45.00 12 40.00 
Total 60 100 30 100 
Chi-Square 
Value 0.20 
p-value 0.65 
Significant Not Significant 
 
 
 Table 1 and bar chart represent the gender wise distribution of cases and 
controls and the p value obtained was 0.65 not significant. 
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TABLE 2: MEAN AGE OF STUDY GROUP AND CONTROL GROUP 
Age 
GROUP 
CASES CONTROLS 
Mean 
(Years) 51.67 52.53 
SD 11.57 9.01 
t-value 0.36 
p-value 0.72 
Significant Not Significant 
 
 
 Table 2 and bar chart represent the mean age between the cases and 
controls, p value-0.72 was not significant  
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TABLE 3: KLOTHO BY STUDY GROUP AND CONTROL GROUP 
KLOTHO 
GROUP 
CASES CONTROLS 
Mean 3.33 5.61 
SD 1.37 2.12 
t-value 6.18 
p-value 0.001 
Significant Highly Significant 
 
 
 
 
 Table 3 and bar chart shows the comparison of Klotho between cases and 
controls. The mean Klotho level in control group- 5.61 ± 2.12 ng/mL and CKD 
cases – 3.33±1.37 ng/mL. A highly significant p value 0.001 was obtained. 
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 The bar diagram compares serum Klotho levels between various eGFR 
categories in the CKD cases. 
 
TABLE 4: FGF 23 BY STUDY GROUP AND CONTROL GROUP 
FGF23 
GROUP 
CASES CONTROLS 
Mean 337.17 221.67 
SD 156.17 37.13 
t-value 3.98 
p-value 0.001 
Significant Highly Significant 
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 Table 5 shows the comparison of FGF23 between cases and control .The 
mean FGF23 in control group- 221.67±37.13 pg/mL and CKD cases- 337.17± 
156.17 pg/mL. A highly significant P value 0.001 was obtained 
 
 
The bar diagram compares serum FGF 23 levels between various eGFR categories 
in the CKD cases. 
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TABLE 5: CREATININEBY STUDY GROUP AND CONTROL GROUP 
CRE FINAL 
GROUP 
CASES CONTROLS 
Mean 2.81 0.76 
SD 2.25 0.19 
t-value 4.97 
p-value 0.001 
Significant Highly Significant 
 
 
 
 Table 5 and bar chart shows the comparison of creatinine between cases 
and control. The mean creatinine level in control group- 0.76± 0.19mg/dL and 
CKD cases - 2.81±2.25mg/dL. A highly significant p value 0.001 was obtained. 
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TABLE 6: UREA BY STUDY GROUP AND CONTROL GROUP 
UREA 
GROUP 
CASES CONTROLS 
Mean 57.90 27.80 
SD 33.51 7.48 
t-value 4.85 
p-value 0.001 
Significant Highly Significant 
 
 
 
 Table 6 and bar chart shows the comparison of urea between cases and 
control. The mean urea level in control group- 27.8± 7.48mg/dL and CKD cases –
57.9±33.51mg/dL. A highly significant p value 0.001 was obtained. 
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TABLE 7: CALCIUM BY STUDY GROUP AND CONTROL GROUP 
CALCIUM 
GROUP 
CASES CONTROLS 
Mean 8.34 9.33 
SD 1.03 0.83 
t-value 4.57 
p-value 0.001 
Significant Highly Significant 
 
 
 
 Table 7 and bar chart shows the comparison of calcium between cases and 
control. The mean calcium level in control group- 9.33± 0.83mg/dL and CKD 
cases –8.34±1.03mg/dL. A highly significant p value 0.001 was obtained. 
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TABLE 8:  PHOSPHATE BY STUDY GROUP AND CONTROL GROUP 
PHOSPHATE 
GROUP 
CASES CONTROLS 
Mean 3.66 3.50 
SD 1.14 0.46 
t-value 0.74 
p-value 0.46 
Significant Not Significant 
 
 
 
 Table 8 and bar chart shows the comparison of phosphate between cases 
and control. The mean phosphate level in control group- 3.5± 0.46mg/dL and 
CKD cases –3.66±1.14mg/dL. p value obtained is 0.46 which is not significant. 
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TABLE 9: PCR BY STUDY GROUP AND CONTROL GROUP 
 
GROUP 
CASES CONTROL 
Mean 2.17 0.09 
SD 2.89 0.05 
t-value 3.95 
p-value 0.001 
Significant Highly Significant 
 
 
 
 Table 7 and bar chart shows the comparison of protein creatinine ratio 
between cases and control. The mean PCR in control group- 0.09± 0.05 and CKD 
cases –2.17±2.89. A highly significant p value 0.001 was obtained. 
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TABLE 10: PTH BY STUDY GROUP AND CONTROL GROUP 
PTH 
GROUP 
CASES CONTROLS 
Mean 90.15 25.50 
SD 112.95 12.02 
t-value 3.12 
p-value 0.002 
Significant Highly Significant 
 
 
 
 
 Table 10 and bar chart shows the comparison of parathyroid hormone 
levels between cases and control. The mean PTH in control group- 25.5pg/mL and 
CKD cases –90.15pg/mL. A highly significant p value 0.001 was obtained. 
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TABLE 11: DIAGNOSIS 
SLNO Diagnosis Number Percentage 
1 ANALGESIC ABUSE 1 1.67 
2 ATN / CKD /POISONING 1 1.67 
3 CIN 2 3.33 
4 DM 9 15.00 
5 DM /CAD 1 1.67 
6 DM / FSGS 1 1.67 
7 DM /HYPOTHYROIDISM 2 3.33 
8 DM / SHT 21 35.00 
9 DM / SHT / IGA 1 1.67 
10 HT / CIN / MN 1 1.67 
11 IGA NEP 5 8.32 
12 PT 1 1.67 
13 SHT 11 18.32 
14 SHT /CIN 1 1.67 
15 SHT / SNAKE BITE 1 1.67 
16 YOUNG STROKE / HT 1 1.67 
 TOTAL 60 100 
 
 Table 11 shows the various etiology for chronic kidney disease in the study 
population. 
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Table 12:  
 
Correlation between Klotho and eGFR (cases) 
 
r (correlation) 0.22 
Significant at 0.05 
 
 
Correlation between Klotho and eGFR (controls) 
r (correlation) 0.03 
Significant at - 
 
 
 
 Table12 and figure show the correlation between Klotho and eGFR. R 
value is 0.22 and Klotho and eGFR are positively correlated. 
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Table 13: 
Correlation between eGFR and FGF23 (cases) 
r (correlation) -0.58 
Significant at 0.001 
 
 
Correlation between eGFR and FGF23 (controls) 
r (correlation) -0.24 
Significant at - 
 
 
 Table13 and figure shows the correlation between FGF 23 and eGFR.  
R value is –0.58and FGF 23 and eGFR are negatively correlated. 
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Table 14: 
 
Correlation between Klotho and FGF23 (Cases) 
r (correlation) -0.40 
Significant at 0.002 
 
Correlation between Klotho and FGF23 (Control) 
r (correlation) -0.47 
Significant at 0.01 
 
 
 
 Table 14 and figure shows the correlation between Klotho and FGF23. R 
value is –0.40 and Klotho and FGF 23 are negatively correlated. 
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Area Under the Curve 
Test Result Variable(s):   Klotho 
Area Std. Errora Asymptotic Sig.b 
Asymptotic 95%  
Confidence Interval 
Lower Bound Upper Bound 
.872 .036 .000 .801 .942 
Cut off value : 3.74 
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Area Under the Curve 
Test Result Variable(s): FGF 23 
Area Std. Errora 
Asymptoti
c Sig.b 
Asymptotic 95%  
Confidence Interval 
Lower 
Bound Upper Bound 
0.768 .048 .000 .673 .862 
Cut off:260.5 
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Regression table 
Model Summary 
Model R R Square Adjusted R Square Std. Error of the Estimate 
1 .804a .646 .611 27.047 
a. Predictors: (Constant), PTH, PCR, Klotho,  
Phosphate, Calcium, Creatinine, FGF 23, Urea 
 
 
coefficientsa 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients t Sig. 
B Std. Error Beta 
1 
(Constant) 89.333 33.034  2.704 .008 
KLOTHO 3.419 1.743 .155 1.962 .053 
FGF23 -.034 .037 -.109 -.913 .364 
CREATININE -6.447 3.149 -.309 -2.047 .044 
UREA -.473 .227 -.339 -2.083 .040 
CALCIUM -1.110 3.698 -.028 -.300 .765 
PHOSPHATE 7.149 3.924 .160 1.822 .072 
PCR -2.478 1.214 -.146 -2.041 .044 
PTH -.025 .052 -.056 -.478 .634 
a. Dependent Variable: eGFR    
 
Discussion 
  
70 
 
DISCUSSION 
 
 The present study aims to correlate serum soluble α Klotho and FGF23 
levels in chronic kidney disease as they have important roles in the pathogenesis 
of CKD-MBD and predictive markers for CKD progression. 
 
In the present study we recruited people in two groups 
Group 1: Chronic kidney disease cases 
Group 2:  Controls 
 
 From tables 1 and 2 there is no significant difference between the groups 
with respect to age and sex. 
 
 The mean Klotho levels in control group are 5.61 ± 2.12 ng/mL and CKD 
cases – 3.33 ± 1.37 ng/mL. A highly significant p value of 0.001 was obtained.  
 
 The mean FGF 23 in control group- 221.67 ± 37.13 pg/mL and CKD cases-
337.17 ± 156.17 pg/mL. A highly significant p value of 0.001 was obtained. 
 
 In concordance with experimental models of CKD and with papers in the 
literature our patients showed strikingly reduced serum soluble α-Klotho levels 
and considerably increased FGF 23 levels as compared to reference control(77). 
 
 Likewise our mean values of Klotho and FGF23 in CKD and in normal 
controls are comparable to those in the literature that employ our same method of 
assay(78). 
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Figure 8: Changes in serum parameters during progression of chronic kidney 
disease. 
Courtesy: John et al. Am J Kidney Dis.2011 July; 58(1):127-134 
 
Correlation between Klotho and eGFR was done and they were positively 
correlated with r value of 0.22. 
 
Correlation between FGF23 and eGFR was done and they were negatively 
correlated with r value of -0.58 
 
Correlation between Klotho and FGF23 was done and they are negatively 
correlated with r value of -0.40. 
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Renal function negatively afflicted s-Klotho levels with detectable 
reduction starting from CKD stage 2. Since s-Klotho is usually excreted via urine, 
this reduction in serum levels along with progression of renal damage can be 
explained by diminished renal synthesis. 
 
 “In case of stable renal Klotho production a reduced excretion due to renal 
damage would increase serum levels. Alternatively if renal excretion persisted to 
be normal, serum levels would not decrease considerably. On the contrary 
increased renal excretion seems highly improbable since there is available clinical 
and experimental data of reduced urinary s-Klotho in CKD”. 
 
 Serum levels of FGF 23 were elevated in CKD population on comparing 
with healthy individuals, with increments detectable since CKD stage 2. 
Correlations of FGF 23 were negative with eGFR. These data suggest that bone 
cells somehow detect the reduction of GFR very early and increase FGF 23 
synthesis, chiefly to decrease vitamin D synthesis and to maintain phosphate 
concentration within normal range. 
 
 The consensual increase of serum phosphate, PTH and FGF 23 in CKD 
individuals can be secondary to the reduction of renal function. 
 
 In the present study a negative relationship emerged between s-Klotho and 
FGF 23 .This supports the hypothesis that s-Klotho whose levels in circulation are 
highly associated to renal function are most likely secondary to reduced 
expression of trans membrane Klotho, which can be considered as a sensitive 
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marker of trans membrane Klotho expression. Thus it explains early development 
of tubular resistance to FGF 23. The synthesis ofFGF23 in a state of 
hyperphosphatemia increases considerably in the bone. 
 
 A recent literature with histological data from patients with 
glomerulonephritis showed parallel reduction of renal Klotho and of s-Klotho 
together with increments in FGF 23, which is in agreement with our data(79). 
 
 Transgenic animals selectively null for renal Klotho have negligible 
shedding of Klotho from renal explants and circulating levels reduced by 80%, 
thus revealing the kidney as a major contributor of circulating Klotho(23). 
 
 FGF 23 is not just a marker of the derangements of calcium – phosphate 
metabolism in CKD but a causative factor for secondary hyperparathyroidism and 
for cardiovascular mortality and morbidity. 
 
 FGF 23 may reveal information about phosphate related toxicity that 
cannot be obtained by measurements of serum phosphate. 
 
 FGF 23 could represent a promising therapeutic target that might improve 
the prognosis of CKD. 
 
In our study serum Klotho and FGF 23 levels have started showing 
significant changes from early stages of CKD but with substantially normal values 
of calcium and phosphate. The significant changes in calcium and phosphate were 
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seen only in late stage of CKD. Similarly significant changes in PTH were 
observed from stage III of CKD. 
 
This confirms that changes in serum calcium and phosphate are not reliable 
to detect early CKD-MBD while s-Klotho and FGF23 seem more sensitive than 
PTH and vitamin D. 
 
From table 11, the commonest etiology predisposing to CKD in our 
population was found to be diabetes mellitus and hypertension. 
 
To evaluate the operating characteristics of Klotho and FGF23 as a 
prognostic tool for the progression of kidney disease we performed receiver 
operating characteristic curve analysis for Klotho and FGF 23. 
 
For serum soluble α-Klotho the area under the curve is 0.872 at 95% 
confidence interval and the cut off level is 3.74 with sensitivity of 87% and 
specificity of 83%. 
 
 For FGF 23 the area under the curve is 0.768 at 95% confidence interval 
and the cut off is 260.5 with sensitivity of 76% and  specificity of 80%. 
 
 Multiple regression analysis was performed to evaluate relationship 
between eGFR and other parameters (Klotho, FGF23, creatinine, urea, PTH, 
calcium, phosphate and urine PCR). Even though Klotho and FGF 23 were not 
independent predictors for chronic kidney disease they have good correlation with 
disease progression. 
Conclusion 
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CONCLUSION 
 
 The study of serum soluble α Klotho and FGF 23 levels in chronic kidney 
disease has been undertaken to unravel the various linking wires to highlight the 
values and establish the role of the interlinked novel markers. 
 
 Several analytical procedures have been put forth while tabulating the 
results of the various parameters of this study along with the relevant statistical 
evaluation. 
 
Therefore, we conclude that 
 Serum soluble α-Klotho decreases in chronic kidney disease. 
 Fibroblast growth factor 23 increases in chronic kidney disease. 
 There is a significant positive correlation between Klotho and eGFR. 
 There is a significant negative correlation between FGF 23 and eGFR. 
 There is a significant negative correlation between Klotho and FGF 23. 
 Changes in Klotho and FGF 23 precede the changes in PTH, vitamin D, 
calcium and phosphate. 
 
 Therefore Klotho and FGF 23 may be used as prognostic markers of CKD 
progression and complications. 
 
  
Limitations of the Study 
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LIMITATIONS OF THE STUDY 
 
 Patients with early stages of CKD are included in the study more than 
those with later stages to prove it as an early biomarker. 
 
 Similarly patients on hemodialysis and who were on renal transplant were 
not included in the study. 
 
 e GFR is calculated using creatinine based equation. It would be better to 
measure GFR using inulin clearance. 
 
  
 
 
 
 
 
 
Scope for Further Studies 
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FURTHER SCOPE OF THE STUDY 
 
 FGF23 functions as a circulating factor that can directly attribute to cardiac 
hypertrophy, inflammation and impaired host response in CKD. Further studies 
can be done to assess the Klotho and FGF 23 levels in CKD associated 
complications. 
 
 Novel analytical methods have to be developed to estimate Klotho and 
FGF 23 both in vitro and in vivo 
 
 Widening the knowledge of FGF 23 –FGFR biology will ultimately lead to 
the discovery of novel drug targets and the advancement of pharmacological 
interventions that reduce the burden of cardiovascular complications, decrease 
systemic inflammation, prevent infections and prolong kidney transplant survival 
and ultimately decreased mortality. 
 
 Further clinical studies could be done to emphasize the potential 
differences in gender, ethnicity and genetic characteristics. 
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